Anne Danks

Dr. Danks has 25 years of experience in nonclinical discovery and development of small molecule therapeutics for CNS disorders, successfully shepherding compounds into first in human and proof of concept clinical trials. She has built and headed small and large preclinical teams, directing all aspects of Pharmacology, Drug Metabolism and Pharmacokinetics (DMPK), Toxicology and Translational Medicine, responsible for development strategy and execution. Prior to joining Longboard, Dr. Danks was Vice President of Preclinical Development at Autobahn Therapeutics after having held the same position at Dart NeuroScience (DNS) for nearly 10 years. Prior to DNS, she held positions of increasing responsibility at TorreyPines Therapeutics, Merck Research Labs, SIBIA Neurosciences, Nereus Pharmaceuticals and Cypros Pharmaceuticals. Dr. Danks completed postdoctoral training at the University of California, Irvine, after receiving her Ph.D. and M.A. degrees in Psychobiology from the State University of New York at Binghamton, and B.A. in Psychology from Marquette University.